Author:
Yaish Hassan M.,Chang Eugenia
Publisher
Springer Berlin Heidelberg
Reference55 articles.
1. Bajaj SP, Thompson AR (2006) Molecular and structural biology of factor IX. Chapter 7. In: Colman RW et al (eds) Hemostasis and thrombosis: basic principles and clinical practice, 5th edn. Lippincott-Raven, Philadelphia, pp 131–150
2. Bray GL, Luban NL (1987) Hemophilia presenting with intracranial hemorrhage. A approach to the infant with intracranial bleeding and coagulopathy. Am J Dis Child 141:1215–1217
3. Castaman G, Tosetto A, Goodeve A, Federici AB, Lethagen S, Budde U, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Habart D, Hill F, Peake I, Rodeghiero F (2010) The impact of bleeding history, von Willebrand factor and PFA-100(®) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. Br J Haematol 151(3):245–251, Epub 25 Aug 2010
4. Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B, rAHF-PFM Study Group (2009) Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 7(3):413–420
5. Coppola A, Di Minno MN, Santagostino E (2010) Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 150(5):515–528. Epub 22 June 2010